Abatacept downregulates Fcγ receptor I on circulating monocytes: a potential therapeutic mechanism in patients with rheumatoid arthritis

Abatacept downregulates Fcγ receptor I on circulating monocytes: a potential therapeutic mechanism in patients with rheumatoid arthritis

Abstract Background Abatacept is a recombinant fusion protein composed of the extracellular domain of cytotoxic T-lymphocyte antigen 4 and the Fc portion of immunoglobulin (Ig) G. The mechanism of action of abatacept in rheumatoid arthritis (RA) is believed to be competitive inhibition of T cell cos...

Full description

Bibliographic Details
Main Authors: Ryosuke Fukue, Yuka Okazaki, Takahisa Gono, Masataka Kuwana
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Abatacept
Monocytes
Fcγ receptors
Anti-citrullinated peptide antibody
Cytokine
Online Access:https://doi.org/10.1186/s13075-022-02886-8

Internet

https://doi.org/10.1186/s13075-022-02886-8

Similar Items